On day 21 after treatment, anti-CXCL16 treatment reduced leukemia cell infiltration in the spleen (Fig. 7j); the spleen weight (Fig. 7k); the populations of immature blast cells in the PB and spleen (Fig. 7l); the percentages of B220dim CD19+ cells in the PB, BM, spleen and LNs (Fig. 7m); and the percentage of Ki-67+ cells in the spleen (Fig. 7n). The gene discussed is CXCL16; the disease is leukemia.